Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies

被引:29
作者
Chao, Debra T. [1 ]
Ma, Xiaohong [1 ]
Li, Olga [1 ]
Park, Hyunjoo [1 ]
Law, Debbie [1 ]
机构
[1] PDL BioPharma Inc, Res Dept, Redwood City, CA 94063 USA
关键词
CD3; Monoclonal antibody; Inflammatory Bowel Disease; T cells; VERSUS-HOST-DISEASE; REGULATORY T-CELLS; MONOCLONAL-ANTIBODY; AUTOIMMUNE ENCEPHALOMYELITIS; ANTI-CD3-EPSILON F(AB')(2); RECEPTOR-BINDING; PHASE-I; OKT3; VISILIZUMAB; ACTIVATION;
D O I
10.1080/08820130802608238
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several low- or non-FcR binding anti-human CD3 monoclonal antibodies have been under investigation for the treatment of autoimmune diseases. To model the mechanism of action of these anti-human CD3 mAbs in the murine system, an Fc-modified anti-mouse CD3 antibody (N297A) was generated. N297A exhibited similar biological effects as Fc-modified anti-human CD3 antibodies including rapid, reversible reduction in peripheral leukocyte numbers, differential modulation of activated versus resting T cells, and reduced levels of induced cytokine release compared to the non-Fc-modified parent antibody. In an in vivo model of colitis induced by adoptive transfer of IL-10-deficient cells, administration of N297A significantly reduced body weight loss. As N297A shared many functional characteristics of non-FcR binding anti-human CD3 mAbs both in vitro and in vivo, it provides a means to model the mechanisms of action of Fc-modified anti-human CD3 antibodies in mouse.
引用
收藏
页码:76 / 92
页数:17
相关论文
共 37 条
[1]  
ALEGRE ML, 1991, J IMMUNOL, V146, P1184
[2]  
ALEGRE ML, 1995, J IMMUNOL, V155, P1544
[3]   TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs [J].
Bisikirska, B ;
Colgan, J ;
Luban, J ;
Bluestone, JA ;
Herold, KC .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2904-2913
[4]   Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells [J].
Carpenter, PA ;
Pavlovic, S ;
Tso, JY ;
Press, OW ;
Gooley, T ;
Yu, XZ ;
Anasetti, C .
JOURNAL OF IMMUNOLOGY, 2000, 165 (11) :6205-6213
[5]   A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease [J].
Carpenter, PA ;
Appelbaum, FR ;
Corey, L ;
Deeg, HJ ;
Doney, K ;
Gooley, T ;
Krueger, J ;
Martin, P ;
Pavlovic, S ;
Sanders, J ;
Slattery, J ;
Levitt, D ;
Storb, R ;
Woolfrey, A ;
Anasetti, C .
BLOOD, 2002, 99 (08) :2712-2719
[6]   A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease [J].
Carpenter, PA ;
Lowder, J ;
Johnston, L ;
Frangoul, H ;
Khoury, H ;
Parker, P ;
Jerome, KR ;
McCune, JS ;
Storer, B ;
Martin, P ;
Appelbaum, F ;
Abonour, R ;
Westervelt, P ;
Anasetti, C .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (06) :465-471
[7]   HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro [J].
Cole, MS ;
Stellrecht, KE ;
Shi, JD ;
Homola, M ;
Hsu, DH ;
Anasetti, C ;
Vasquez, M ;
Tso, JY .
TRANSPLANTATION, 1999, 68 (04) :563-571
[8]  
Cole MS, 1997, J IMMUNOL, V159, P3613
[9]   T helper cell 1-type CD4(+) T cells, but not B cells, mediate colitis in interleukin 10-deficient mice [J].
Davidson, NJ ;
Leach, MW ;
Fort, MM ;
ThompsonSnipes, L ;
Kuhn, R ;
Muller, W ;
Berg, DJ ;
Rennick, DM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (01) :241-251
[10]   Cutting edge:: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-γ production and proliferation of CD8+ T cells [J].
Endharti, AT ;
Rifa'I, M ;
Shi, Z ;
Fukuoka, Y ;
Nakahara, Y ;
Kawamoto, Y ;
Takeda, K ;
Isobe, K ;
Suzuki, H .
JOURNAL OF IMMUNOLOGY, 2005, 175 (11) :7093-7097